Wu Yun, Fan Qing, Liu Xiaojing, Cao Yajing, Yang Jin, Yan Yu, Tao Hui, Zhang Fuhe, Zhang Linglin, Wang Peiru, Wang Xiuli
Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200443, China.
Department of Dermatology, Shanghai Fengxian District Central Hospital, Shanghai, 201499, China.
Photodiagnosis Photodyn Ther. 2025 Feb;51:104474. doi: 10.1016/j.pdpdt.2025.104474. Epub 2025 Jan 7.
Photodynamic therapy (PDT) is beneficial for managing rosacea, and chlorin e6 derivative-mediated photodynamic therapy (STBF-PDT) has demonstrated efficacy in reducing acne lesions with mild adverse reactions.
This study aimed to assess the effectiveness and safety of STBF-PDT for the treatment of moderate-to-severe rosacea.
In this prospective, randomised, evaluator-blind controlled study, patients with moderate-to-severe rosacea were assigned to receive up to six STBF-PDT sessions or 100 mg of doxycycline daily for eight weeks, followed by a 24-week follow-up.
A total of 76 patients were enrolled (38 assigned to STBF-PDT and 38 to oral doxycycline) with 69 (36 in the STBF-PDT group and 33 in the doxycycline group) completing the study. At the end of treatment, the median reduction in lesion count was 82.3 % in the STBF-PDT group and 81.8 % in the doxycycline group, indicating no significant difference between the groups. The STBF-PDT group exhibited a lower relapse rate and a significantly higher reduction in Demodex mites. Clinician's Erythema Assessment success (CEA), sensations of burning and pruritus, telangiectasia, and Rosacea-related Quality of Life (RosaQoL) scores were comparable between groups. No severe adverse reactions were observed.
STBF-PDT is a promising treatment option for mild-to-moderate rosacea with mild adverse reactions.
光动力疗法（PDT）对治疗酒渣鼻有益，二氢卟吩e6衍生物介导的光动力疗法（STBF-PDT）已证明在减少痤疮皮损方面有效，且不良反应轻微。
本研究旨在评估STBF-PDT治疗中重度酒渣鼻的有效性和安全性。
在这项前瞻性、随机、评估者盲法对照研究中，中重度酒渣鼻患者被分配接受最多6次STBF-PDT治疗或每日口服100 mg强力霉素，持续8周，随后进行24周的随访。
共纳入76例患者（38例分配至STBF-PDT组，38例分配至口服强力霉素组），69例（STBF-PDT组36例，强力霉素组33例）完成研究。治疗结束时，STBF-PDT组皮损计数的中位数减少82.3%，强力霉素组减少81.8%，两组之间无显著差异。STBF-PDT组的复发率较低，毛囊蠕形螨减少显著更多。两组之间临床医生红斑评估成功率（CEA）、烧灼感和瘙痒感、毛细血管扩张以及酒渣鼻相关生活质量（RosaQoL）评分相当。未观察到严重不良反应。
STBF-PDT是治疗轻至中度酒渣鼻且不良反应轻微的一种有前景的治疗选择。
